Lv12
30 积分 2021-07-05 加入
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
1小时前
待确认
New promises and challenges in the treatment of advanced non-small-cell lung cancer
23小时前
已完结
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b)
4天前
已完结
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
5天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
20天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
20天前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
1个月前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
1个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
1个月前
已完结
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
1个月前
已完结
皖公网安备34019202002308
